Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

McEachern

Showing results (381-390 of 493) with videos related to

Pageof 50
Sort By:
Infection and Immunity|September 2, 2020
Cigarette Smoke Exposure Promotes Virulence of Pseudomonas aeruginosa and Induces Resistance to Neutrophil KillingJason Chien, John H Hwang, Sedtavut Nilaad, et al.
Clinical Trials (London, England)|May 16, 2017
Recommendations for data monitoring committees from the Clinical Trials Transformation InitiativeKarim A Calis, Patrick Archdeacon, Raymond Bain, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2007
A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humansKaw Bing Chua, Gary Crameri, Alex Hyatt, et al.
Journal of Medicinal Chemistry|June 22, 2013
A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in miceYujun Zhao, Shanghai Yu, Wei Sun, et al.
Journal of Medicinal Chemistry|April 28, 2020
Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong <i>In Vivo</i> Antitumor ActivityShilin Xu, Angelo Aguilar, Liyue Huang, et al.
Journal of Medicinal Chemistry|June 13, 2025
MD-4251: A First-in-Class Oral MDM2 Degrader Inducing Complete Tumor Regression with Single-Dose AdministrationRanjan Kumar Acharyya, Liyue Huang, Angelo Aguilar, et al.
Journal of Immunological Methods|January 15, 2008
Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal speciesMeng Yu, Vicky Stevens, Jody D Berry, et al.
Journal of Medicinal Chemistry|November 26, 2009
Potent and orally active small-molecule inhibitors of the MDM2-p53 interactionShanghai Yu, Dongguang Qin, Sanjeev Shangary, et al.
Artificial Organs|April 22, 2016
Topical Polymyxin-Trimethoprim Prophylaxis May Decrease the Incidence of Driveline Infections in Patients With Continuous-Flow Left Ventricular Assist DevicesMarlene L Durand, Stephanie C Ennis, Joshua N Baker, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2021
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trialAmita Patnaik, Glen J Weiss, Drew W Rasco, et al.
Pageof 50

Showing results (381-390 of 493) with videos related to

Sort By:
Pageof 50
Infection and Immunity|September 2, 2020
Cigarette Smoke Exposure Promotes Virulence of Pseudomonas aeruginosa and Induces Resistance to Neutrophil KillingJason Chien, John H Hwang, Sedtavut Nilaad, et al.
Clinical Trials (London, England)|May 16, 2017
Recommendations for data monitoring committees from the Clinical Trials Transformation InitiativeKarim A Calis, Patrick Archdeacon, Raymond Bain, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2007
A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humansKaw Bing Chua, Gary Crameri, Alex Hyatt, et al.
Journal of Medicinal Chemistry|June 22, 2013
A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in miceYujun Zhao, Shanghai Yu, Wei Sun, et al.
Journal of Medicinal Chemistry|April 28, 2020
Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong <i>In Vivo</i> Antitumor ActivityShilin Xu, Angelo Aguilar, Liyue Huang, et al.
Journal of Medicinal Chemistry|June 13, 2025
MD-4251: A First-in-Class Oral MDM2 Degrader Inducing Complete Tumor Regression with Single-Dose AdministrationRanjan Kumar Acharyya, Liyue Huang, Angelo Aguilar, et al.
Journal of Immunological Methods|January 15, 2008
Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal speciesMeng Yu, Vicky Stevens, Jody D Berry, et al.
Journal of Medicinal Chemistry|November 26, 2009
Potent and orally active small-molecule inhibitors of the MDM2-p53 interactionShanghai Yu, Dongguang Qin, Sanjeev Shangary, et al.
Artificial Organs|April 22, 2016
Topical Polymyxin-Trimethoprim Prophylaxis May Decrease the Incidence of Driveline Infections in Patients With Continuous-Flow Left Ventricular Assist DevicesMarlene L Durand, Stephanie C Ennis, Joshua N Baker, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2021
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trialAmita Patnaik, Glen J Weiss, Drew W Rasco, et al.
Pageof 50